MCID: URT033
MIFTS: 30

Urethra Cancer

Categories: Cancer diseases

Aliases & Classifications for Urethra Cancer

MalaCards integrated aliases for Urethra Cancer:

Name: Urethra Cancer 12 15
Malignant Tumour of Urethra 12
Malignant Urethral Neoplasm 12
Cancer of Urethra 12
Urethral Ca 12

Classifications:



External Ids:

Disease Ontology 12 DOID:734
ICD9CM 36 189.3
MeSH 45 D014523
NCIt 51 C7507 C9106
SNOMED-CT 69 94123008
ICD10 34 C68.0

Summaries for Urethra Cancer

Disease Ontology : 12 An urinary tract cancer that derives from the tissues of the urethra.

MalaCards based summary : Urethra Cancer, also known as malignant tumour of urethra, is related to urethra adenocarcinoma and posterior urethra cancer. An important gene associated with Urethra Cancer is FNDC3B (Fibronectin Type III Domain Containing 3B), and among its related pathways/superpathways is Hematopoietic Stem Cell Gene Regulation by GABP alpha/beta Complex. The drugs Carboplatin and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include kidney and endothelial, and related phenotype is homeostasis/metabolism.

Related Diseases for Urethra Cancer

Diseases in the Urethra Cancer family:

Posterior Urethra Cancer Anterior Urethra Cancer

Diseases related to Urethra Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 41)
# Related Disease Score Top Affiliating Genes
1 urethra adenocarcinoma 28.8 ALK AMACR ANKRD28 APP ARID2 ATM
2 posterior urethra cancer 12.1
3 anterior urethra cancer 12.1
4 urethra transitional cell carcinoma 11.1
5 urethral cancer 11.1
6 urethra squamous cell carcinoma 11.0
7 prostate signet ring cell adenocarcinoma 10.2 CEACAM5 KLK3
8 endodermal sinus tumor 10.2 CHGA KLK3
9 vulval paget's disease 10.2 CEACAM5 UPK3A
10 rete testis adenocarcinoma 10.2 CEACAM5 KLK3
11 nodular ganglioneuroblastoma 10.1 ALK CHGA
12 fibroepithelial basal cell carcinoma 10.1 CEACAM5 CHGA
13 vulva adenocarcinoma 10.1 CEACAM5 UPK3A
14 atypical follicular adenoma 10.1 CEACAM5 CHGA
15 pancreatic serous cystadenoma 10.1 CEACAM5 CHGA
16 prostate squamous cell carcinoma 10.1 CEACAM5 KLK3
17 liver sarcoma 10.1 CEACAM5 CHGA
18 nephrogenic adenoma 10.1 AMACR KLK3
19 gastric cardia carcinoma 10.1 CHGA SMAD4
20 radiation cystitis 10.1 KLK3 UPK3A
21 rete testis neoplasm 10.1 CEACAM5 KLK3
22 gastric small cell carcinoma 10.1 CEACAM5 CHGA
23 prostate small cell carcinoma 10.1 AMACR KLK3
24 gallbladder squamous cell carcinoma 10.1 APP CEACAM5
25 binswanger's disease 10.0 APP CHGA
26 prostatic acinar adenocarcinoma 10.0 AMACR KLK3
27 female urethral cancer 10.0 CEACAM5 CHGA KLK3
28 descending colon cancer 10.0 APP CEACAM5
29 pancreatic cystadenoma 10.0 CEACAM5 CHGA
30 urethral diverticulum 10.0 AMACR KLK3 UPK3A
31 telangiectasis 10.0 ATM SMAD4
32 mixed ductal-endocrine carcinoma 10.0 CEACAM5 CHGA SMAD4
33 clear cell adenocarcinoma 9.9 AMACR KLK3 SMAD4
34 endocrine gland cancer 9.9 CEACAM5 CHGA SMAD4
35 gastrointestinal system benign neoplasm 9.9 CEACAM5 CHGA
36 male reproductive organ cancer 9.9 AMACR CHGA KLK3
37 male reproductive system disease 9.9 AMACR CHGA KLK3
38 acinar cell carcinoma 9.9 CHGA SMAD4
39 suppression of tumorigenicity 12 9.5 AMACR CHGA KLK3 SMAD4 UPK3A
40 urethra clear cell adenocarcinoma 8.2 ALK AMACR ANKRD28 APP ARID2 ATM
41 urethral benign neoplasm 7.9 ALK AMACR ANKRD28 APP ARID2 ATM

Graphical network of the top 20 diseases related to Urethra Cancer:



Diseases related to Urethra Cancer

Symptoms & Phenotypes for Urethra Cancer

MGI Mouse Phenotypes related to Urethra Cancer:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.28 ALK AMACR APP ARID2 ATM CHGA

Drugs & Therapeutics for Urethra Cancer

Drugs for Urethra Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 148)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 38904 10339178 498142
2
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 441203 84093 2767
3
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
4
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
5
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
6
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
7
Vinblastine Approved Phase 3,Phase 2,Phase 1 865-21-4 13342 241903
8
leucovorin Approved Phase 3,Phase 2 58-05-9 6006 143
9
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
10
Ramucirumab Approved, Investigational Phase 3,Phase 2,Phase 1 947687-13-0
11
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124
12
Bevacizumab Approved, Investigational Phase 3 216974-75-3
13
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
14
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
15 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
16 Antimetabolites Phase 3,Phase 2,Phase 1
17 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
18 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
19 Immunologic Factors Phase 3,Phase 2,Phase 1
20 Antiviral Agents Phase 3,Phase 2,Phase 1
21 Anti-Infective Agents Phase 3,Phase 2,Phase 1
22 Peripheral Nervous System Agents Phase 3,Phase 1,Phase 2
23 Cola Phase 3,Phase 1,Not Applicable
24 Analgesics Phase 3,Phase 1,Phase 2
25 Liver Extracts Phase 3,Phase 1,Not Applicable
26 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
27 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
28 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
29 Vitamin B Complex Phase 3,Phase 2
30 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
31 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
32 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
33 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
34 Antimitotic Agents Phase 3,Phase 2,Phase 1
35 Vitamin B9 Phase 3,Phase 2
36 Folate Phase 3,Phase 2
37 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
38 Dermatologic Agents Phase 3,Phase 2,Phase 1
39 Antirheumatic Agents Phase 3,Phase 2
40 Folic Acid Antagonists Phase 3,Phase 2
41 Analgesics, Opioid Phase 3
42 Central Nervous System Depressants Phase 3
43 Narcotics Phase 3
44 Anesthetics Phase 3
45 Anesthetics, Intravenous Phase 3
46 Adjuvants, Anesthesia Phase 3
47 Anesthetics, General Phase 3
48 Antineoplastic Agents, Immunological Phase 3,Phase 2,Phase 1
49 Immunoglobulins Phase 3,Phase 2,Phase 1
50 Immunoglobulin G Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 81)
# Name Status NCT ID Phase Drugs
1 Combination Chemotherapy in Treating Patients With Bladder Cancer Completed NCT00003701 Phase 3 carboplatin;cisplatin;doxorubicin hydrochloride;methotrexate;paclitaxel;vinblastine sulfate
2 Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium Completed NCT00003376 Phase 3 carboplatin;cisplatin;doxorubicin hydrochloride;methotrexate;paclitaxel;vinblastine
3 Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer Completed NCT00022191 Phase 3 cisplatin;gemcitabine hydrochloride;paclitaxel
4 Combination Chemotherapy in Treating Patients With Transitional Cell Cancer of the Urothelium Completed NCT00014274 Phase 2, Phase 3 carboplatin;gemcitabine hydrochloride;methotrexate;vinblastine sulfate
5 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
6 Four Cycles Versus Six Cycles of Cisplatin-based Chemotherapy in Metastatic Urothelial Carcinoma Recruiting NCT03296306 Phase 3 Treatment duration of cisplatin based chemotherapy
7 Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Active, not recruiting NCT00942331 Phase 3 Cisplatin;Gemcitabine Hydrochloride
8 A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer Active, not recruiting NCT02426125 Phase 3 Ramucirumab;Docetaxel;Placebo
9 Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer Unknown status NCT01118039 Phase 2 sunitinib malate
10 Surgery Plus Combination Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Urinary Tract Unknown status NCT00006111 Phase 2 cisplatin;fluorouracil
11 A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer Unknown status NCT01326871 Phase 1, Phase 2 Cisplatin;Gemcitabine
12 Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer Unknown status NCT01191892 Phase 2 carboplatin;gemcitabine hydrochloride;vandetanib;Placebo
13 Pazopanib Hydrochloride in Treating Patients With Metastatic Urethral Cancer or Bladder Cancer That Has Relapsed or Not Responded to Treatment Completed NCT01031875 Phase 2 pazopanib hydrochloride
14 S0121, Neoadjuvant Carboplatin, Paclitaxel, and Gemcitabine Followed by Cisplatin and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Carcinoma of the Urothelium Completed NCT00055835 Phase 2 carboplatin;cisplatin;gemcitabine hydrochloride;paclitaxel
15 Combination Chemotherapy in Patients With Advanced Urinary Tract Cancer Completed NCT00002684 Phase 2 cisplatin;ifosfamide;paclitaxel
16 Neoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radical Cystectomy for Locally Advanced Carcinoma (Cancer) of the Urothelium Completed NCT00080795 Phase 2 cisplatin;doxorubicin hydrochloride;gemcitabine hydrochloride;ifosfamide
17 Fluorouracil in Treating Patients With Recurrent or Metastatic Bladder Cancer Completed NCT00003175 Phase 2 fluorouracil
18 Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT) Completed NCT01089088 Phase 2 cisplatin;gemcitabine hydrochloride;sunitinib malate
19 Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium Completed NCT01090466 Phase 1, Phase 2 cisplatin;gemcitabine hydrochloride;temsirolimus
20 Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium Completed NCT00397488 Phase 2 sunitinib malate
21 S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract Completed NCT00014144 Phase 2 gefitinib
22 Nitrocamptothecin in Treating Patients With Metastatic Cancer of the Urinary Tract Completed NCT00006026 Phase 2 rubitecan
23 SCH 66336 Plus Gemcitabine in Treating Patients With Advanced Cancer of the Urinary Tract Completed NCT00006351 Phase 2 gemcitabine hydrochloride;lonafarnib
24 S0306, Irinotecan in Treating Patients With Recurrent or Refractory Advanced Transitional Cell Cancer of the Urothelium Previously Treated With Chemotherapy Completed NCT00066612 Phase 2 irinotecan hydrochloride
25 Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium and Decreased Kidney Function Completed NCT00005644 Phase 2 gemcitabine hydrochloride;paclitaxel
26 Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium Completed NCT00053209 Phase 2 gemcitabine hydrochloride;pemetrexed disodium
27 S0219, Combination Chemotherapy Followed By Observation or Surgery in Patients With Stage II or Stage III Cancer of the Urothelium Completed NCT00045630 Phase 2 carboplatin;gemcitabine;paclitaxel
28 Piritrexim in Treating Patients With Advanced Cancer of the Urinary Tract Completed NCT00002914 Phase 2 piritrexim
29 Docetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder Cancer Completed NCT00004223 Phase 2 docetaxel;gemcitabine hydrochloride
30 A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer Completed NCT00661609 Phase 2 AZD4877
31 Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma Completed NCT01282463 Phase 2 Docetaxel
32 Arsenic Trioxide in Treating Patients With Urothelial Cancer Completed NCT00009867 Phase 2 arsenic trioxide
33 Pazopanib in Treating Patients With Metastatic Urothelial Cancer Completed NCT00471536 Phase 2 pazopanib hydrochloride
34 VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium Completed NCT00407485 Phase 2
35 Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function Completed NCT00478361 Phase 2 Gemcitabine hydrochloride;Paclitaxel;Doxorubicin hydrochloride;Pegfilgrastim
36 Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer Completed NCT00021099 Phase 2 ixabepilone
37 Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma Completed NCT00072150 Phase 2 bortezomib
38 Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma Recruiting NCT03179943 Phase 2 Atezolizumab;Guadecitabine
39 Afatinib in Advanced Refractory Urothelial Cancer Recruiting NCT02122172 Phase 2 afatinib dimaleate
40 Sitravatinib and Nivolumab in Urothelial Carcinoma Study Recruiting NCT03606174 Phase 2 Sitravatinib;Nivolumab
41 Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer Recruiting NCT03617913 Phase 2 Avelumab;Cisplatin;Fluorouracil;Mitomycin
42 Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer Recruiting NCT03237780 Phase 2 Atezolizumab;Eribulin Mesylate
43 Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Recruiting NCT03397394 Phase 2 Rucaparib
44 A Trial to Evaluate Pemetrexed Clinical Responses in Relation to Tumor MTAP Gene Status in Patients With Previously Treated Metastatic Urothelial Carcinoma Recruiting NCT02693717 Phase 2 Pemetrexed;Dexamethasone
45 Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant Active, not recruiting NCT00082706 Phase 2 5-Fluorouracil (5-FU);Leucovorin;Cisplatin;Gemcitabine
46 A Trial With Vinflunine in Patients With Metastatic Bladder Cancer and Impaired Renal Function Active, not recruiting NCT02665039 Phase 2 Vinflunine;Gemcitabine;Carboplatin
47 Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery Active, not recruiting NCT02178241 Phase 2 Eribulin Mesylate;Gemcitabine Hydrochloride
48 Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer Active, not recruiting NCT00749892 Phase 2 Erlotinib Hydrochloride
49 Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma Not yet recruiting NCT03513952 Phase 2 Atezolizumab
50 S0400, FR901228 in Treating Patients With Advanced Cancer of the Urothelium Terminated NCT00087295 Phase 2 Depsipeptide

Search NIH Clinical Center for Urethra Cancer

Genetic Tests for Urethra Cancer

Anatomical Context for Urethra Cancer

MalaCards organs/tissues related to Urethra Cancer:

42
Kidney, Endothelial

Publications for Urethra Cancer

Articles related to Urethra Cancer:

# Title Authors Year
1
Treatment and Outcomes of Primary Urethra Cancer. ( 28537991 )
2018

Variations for Urethra Cancer

Expression for Urethra Cancer

Search GEO for disease gene expression data for Urethra Cancer.

Pathways for Urethra Cancer

Pathways related to Urethra Cancer according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 9.97 ATM SMAD4

GO Terms for Urethra Cancer

Sources for Urethra Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....